About inogen inc - INGN
Inogen, Inc. is a global medical technology company offering innovative respiratory products for use in the homecare setting. It supports patient respiratory care by developing, manufacturing, and marketing innovative best-in-class respiratory therapy devices used to deliver care to patients suffering from chronic respiratory conditions. Its products include Inogen One G4 system, Inogen One G3 system, Inogen One G5 system, Inogen TAV, and Inogen at Home. The company was founded by Alison Perry, Alison K. Bauerlein, Brenton Taylor, and Byron Myers on November 27, 2001 and is headquartered in Beverly, MA.
INGN At a Glance
Inogen, Inc.
500 Cummings Center
Beverly, Massachusetts 01915
| Phone | 1-805-562-0500 | Revenue | 348.67M | |
| Industry | Medical Specialties | Net Income | -22,747,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 3.861% | |
| Fiscal Year-end | 12 / 2026 | Employees | 753 | |
| View SEC Filings |
INGN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.513 |
| Price to Book Ratio | 0.952 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -7.894 |
| Enterprise Value to Sales | 0.216 |
| Total Debt to Enterprise Value | 0.232 |
INGN Efficiency
| Revenue/Employee | 463,038.513 |
| Income Per Employee | -30,208.499 |
| Receivables Turnover | 8.972 |
| Total Asset Turnover | 1.172 |
INGN Liquidity
| Current Ratio | 3.121 |
| Quick Ratio | 2.712 |
| Cash Ratio | 1.902 |
INGN Profitability
| Gross Margin | 47.20 |
| Operating Margin | -8.664 |
| Pretax Margin | -6.705 |
| Net Margin | -6.524 |
| Return on Assets | -7.648 |
| Return on Equity | -12.427 |
| Return on Total Capital | -10.847 |
| Return on Invested Capital | -11.46 |
INGN Capital Structure
| Total Debt to Total Equity | 9.091 |
| Total Debt to Total Capital | 8.334 |
| Total Debt to Total Assets | 5.852 |
| Long-Term Debt to Equity | 7.446 |
| Long-Term Debt to Total Capital | 6.825 |